Navigation Links
Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
Date:10/10/2007

BOULDER, Colo. and MONTREAL, Oct. 10 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced the initiation of a Phase One clinical trial evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Taxotere(R) (docetaxel; Sanofi Aventis) in patients with solid tumors. Taxotere is an approved chemotherapy agent marketed for use in breast, lung, prostate, gastric and head and neck cancer.

In the first portion of the trial, MGCD0103 will be given orally, three times per week for three weeks in combination with Taxotere, which will be administered on Day 1 of each three-week cycle to patients with cancer where treatment with Taxotere is approved or considered standard of care, or patients who have no available standard of care therapeutic options. Key objectives for this portion of the study will be threefold: to evaluate the safety of administering these two agents together; determine the maximum tolerated dose of MGCD0103 when combined with the two fixed doses of Taxotere; and to define optimal dosing for the second portion of the trial. In the second portion of the trial, objectives include further assessment of the safety of the drug combination, quantification of tumor responses and measurement of the pharmacodynamic and pharmacokinetic characteristics. The trial may enroll up to 50 patients at cancer centers in North America. The trial is expected to take 12 to 18 months to complete.

"This is an important step forward in the clinical development of MGCD0103," said Andrew Allen, executive vice president and chief medical officer of Pharmion Corporation. "Cytotoxic chemotherapies such
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2014.  Revenue for the quarter was $415.2 ... (a 1 percent decrease on a constant currency basis). Net ... to the quarter ended June 30, 2013. Diluted earnings per ... percent compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Calif., July 31, 2014 Pharmacyclics, Inc. (the "Company") ... recent developments for the quarter ended June 30, 2014. ... June 30, 2014 Revenue Total revenue for the quarter ... million for the quarter ended June 30, 2013 primarily due ... million. Total revenue for the six months ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... Contaminated with Diethylene Glycol,(DEG) Remains a Potential ... Md., May 4, 2007-The U.S. Food and ... repackers, and health professionals who compound,medications to ... a,sweetener commonly used worldwide in liquid over-the-counter ...
... ROCKVILLE, Md., April 25, 2007-The U.S. Food ... a Consent Decree of,Permanent Injunction against PharmaFab ... officials, Mark Tengler, PharmaFab's president,and Russ McMahen, ... the illegal manufacture and distribution of prescription ...
Cached Medicine Technology:FDA Advises Manufacturers to Test Glycerin for Possible,Contamination 2Major Manufacturer of Unapproved and Adulterated Drugs 2Major Manufacturer of Unapproved and Adulterated Drugs 3
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... central role in regulating appetite and whole-body metabolism. A ... control of food intake and body weight, but the ... unclear. A new study in the ... in a type of neuron known as pro-opiomelanocortin (POMC) ... diet. Sabrina Diano and colleagues at Yale University ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
(Date:8/1/2014)... CLEVELAND, Ohio In a first-of-its-kind study, researchers at ... found that lap infants may be at greater risk ... analyzed pediatric medical emergencies on flights worldwide between January ... deaths occurred in children under the age of 2. ... MedAire to characterize the rare event of an in-flight ...
(Date:8/1/2014)... Vegas, NV (PRWEB) August 01, 2014 ... and opportunities for independent community pharmacies. At ThoughtSpot ... pharmacists are equipped with practices and resources to ... Session, AmerisourceBergen leaders focused on critical issues to ... learn, optimize and grow. , ThoughtSpot show ...
Breaking Medicine News(10 mins):Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5
... "Thomson Reuters Citation Laureates" Recognized for Their,Contributions to ... Oct. 1 The Scientific business,of Thomson Reuters ... researchers likely to be in contention for Nobel ... winners to be announced in October., Each ...
... of serious public health issue through first ... Sudden cardiac arrest (SCA) claims,more lives each year ... a new Heart Rhythm Society survey, four out of ... health issue that causes,more than 250,000 deaths each year. ...
... developed a method of using nanoparticles to deliver treatments ... team led by Richard Borgens of the School of ... of Biomedical Engineering coated silica nanoparticles with a polymer ... That research is being published in the October edition ...
... Recession Fears - List Reports Aggregate Revenue of $185 Billion; Nuclear ... 100 Health Companies and No. 1161 on the Inc. 5000 With ... ... (PRWEB) October 1, 2008 -- Inc. today ranked www.mobilenuclear.com [Nuclear Medicine ...
... Ticker Symbol: CUR, QUEBEC CITY, Oct. 1 ... company commercializing high-value cancer diagnostic,tests and delivering laboratory ... CEO of the Company, will be presenting a ... Focus Conference on,Monday, October 6, 2008, at 1:30 ...
... with No Monthly ... Premium, ... serving seniors and others with Medicare,announced today that its new Medicare Advantage ... with no monthly plan premiums and no deductibles., "Access to affordable, ...
Cached Medicine News:Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 2Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 3Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 4Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 5Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 2Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 3Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 4Health News:Researchers use nanoparticles to deliver treatment for brain, spinal cord injuries 2Health News:America's 5000 Fastest-Growing Private Companies Revealed 2Health News:DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008 2Health News:SCAN Health Plan Arizona Announces Its 2009 MAPD Benefits for Maricopa County 2
Inquire...
... Cryptosporidium sps. is now recognized ... patients with HIV infection. Routine parasitological ... Modified Acid Fast staining techniques prove ... Control Slides have many typical organisms ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
Medicine Products: